Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

pproval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2006, and its Forms 10-Q for the quarters ended March 31, 2007, June 30, 2007, and September 30, 2007.

ISTA Pharmaceuticals, Inc.

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006 Revenue:

Product sales, net $ 19,092 $ 12,190 $ 58,589 $ 32,729

License revenue 70 70 278 278 Total revenue 19,162 12,260 58,86
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Md., Aug. 13 PharmAthene, Inc.,(Amex: PIP ... against biological and chemical threats, announced today,that proceedings ... to,affirm the validity of the merger between Healthcare ... Court of Chancery will determine that the Merger ...
... San Francisco Office Doubles Staff; San Diego Office to Offer Regulatory ... ... Image Solutions, Inc. (ISI), a,leader in providing software and services to ... Francisco,office and opening of a new facility in San Diego. The ...
... Addressing Increased Demand for Food, Feed, Fuel, Materials, ... (NYSE: DD ),Chairman and CEO Charles O. ... Thomas M. Connelly, and Group Vice President -- ... investors on DuPont,businesses serving the agriculture and biofuels ...
Cached Biology Technology:Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court 2ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 2ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 3ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 4DuPont Leaders Brief Investors on Agriculture Businesses 2DuPont Leaders Brief Investors on Agriculture Businesses 3
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... , Construction of ENJOY: A Generation House, the U.S. Department ... a collaborative effort of Rutgers, The State University of New ... following a recent ground-breaking at NJIT. Once construction of ... topping-off event at NJIT with major sponsors and VIP guests. ...
... (Boston) Kenneth Walsh, PhD, FAHA, the Aram ... of the Whitaker Cardiovascular Institute at Boston University ... 2011 American Heart Association (AHA) Distinguished Scientist. The ... The AHA created a Distinguished Scientist designation ...
... University biologists identified a new way in which bacteria hijack ... new antibiotics. Zhao-Qing Luo, the associate professor of biological ... new enzyme used by the bacterium Legionella pneumophila ... cell in order to take up residence. "Legionnaires, disease ...
Cached Biology News:Team New Jersey to make precast concrete solar house reality 2BUSM professor selected as American Heart Association Distinguished Scientist 2Purdue biologists identify new strategy used by bacteria during infection 2Purdue biologists identify new strategy used by bacteria during infection 3
Request Info...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Validated and Silencer Pre-designed siRNAs, which are ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: